Apyx Medical Corporation (NASDAQ:APYX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Apyx Medical Corporation (NASDAQ:APYX) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $6.60.

A number of equities research analysts recently weighed in on APYX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. HC Wainwright assumed coverage on shares of Apyx Medical in a research note on Monday, July 13th. They set a “buy” rating and a $7.00 price target for the company. Finally, Zacks Research raised shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th.

Institutional Investors Weigh In On Apyx Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC purchased a new stake in shares of Apyx Medical in the 3rd quarter worth $28,000. Nwam LLC purchased a new position in shares of Apyx Medical during the first quarter valued at $47,000. Osaic Holdings Inc. purchased a new position in shares of Apyx Medical during the second quarter valued at $50,000. Franklin Resources Inc. bought a new stake in shares of Apyx Medical in the third quarter valued at about $59,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Apyx Medical in the second quarter valued at about $62,000. 55.33% of the stock is owned by institutional investors.

Apyx Medical Stock Performance

APYX stock opened at $3.03 on Friday. Apyx Medical has a twelve month low of $1.70 and a twelve month high of $5.08. The firm has a market cap of $127.62 million, a price-to-earnings ratio of -15.15 and a beta of 1.39. The business’s fifty day simple moving average is $4.15 and its two-hundred day simple moving average is $3.91. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $13.88 million during the quarter, compared to analyst estimates of $13.18 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. Analysts predict that Apyx Medical will post -0.25 earnings per share for the current year.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.